Management of Prolonged Bleeding with Normal Platelets, Prolonged PT/INR, and Elevated Anti-Factor Xa

Initial Assessment and Management

The American College of Cardiology recommends immediate discontinuation of anticoagulants, local hemostatic measures, volume resuscitation, and consideration of reversal agents for patients with prolonged bleeding, normal platelets, prolonged PT/INR, and anti-factor Xa >2 1, 2
Discontinue all anticoagulants and antiplatelet agents immediately, secure airway, and establish large-bore intravenous access for volume resuscitation 2
Apply local hemostatic measures and initiate aggressive volume resuscitation with isotonic crystalloids to restore hemodynamic stability 2, 3
Correct hypothermia and acidosis, which can worsen coagulopathy, and involve appropriate specialty services early for definitive management 2

Elevated anti-factor Xa >2 with prolonged PT/INR indicates significant anticoagulant effect, likely from a direct factor Xa inhibitor 3, 4
Normal platelets with prolonged PT/INR suggests the coagulopathy is related to anticoagulant medication rather than consumptive coagulopathy 3
The International Society on Thrombosis and Hemostasis recommends consideration of anticoagulant reversal for patients with serious bleeding and a DOAC level >50 ng/mL 2

For direct factor Xa inhibitors, administer coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) if available, or 4-factor prothrombin complex concentrate (PCC) at a dose of 25-50 IU/kg 5
For unfractionated heparin, administer protamine sulfate: 1 mg per 100 units of heparin administered in the last 2-3 hours (maximum dose: 50 mg) 5, 8
For low molecular weight heparin, administer protamine sulfate: 1 mg per 1 mg of enoxaparin administered in the last 8 hours, noting that protamine reversal is only partially effective for LMWH 5, 8

Transfuse packed red blood cells to maintain hemoglobin ≥7 g/dL (≥8 g/dL in patients with coronary artery disease) 2, 3
Consider anti-fibrinolytic agents such as tranexamic acid or epsilon aminocaproic acid, and platelet transfusion may be considered in specific cases after other measures have failed 3

Monitor hemodynamic status, hemoglobin, and coagulation parameters frequently, and reassess the need for anticoagulation after bleeding is controlled 2, 3
When restarting anticoagulation after major bleeding, consider using anti-Xa monitoring instead of PTT for heparin products, especially if baseline PTT is prolonged 6, 7

Do not delay resuscitation and local hemostatic measures while waiting for reversal agents, and avoid using PT/INR alone to monitor direct Xa inhibitors 2, 3
Do not administer intravenous vitamin K rapidly in patients with mechanical heart valves due to risk of valve thrombosis 9
Be cautious with large volumes of plasma in patients with portal hypertension, and recognize that timing of blood sampling relative to anticoagulant administration can affect interpretation of coagulation tests 3, 8